Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2019

View Archived Issues

Genetic ablation of CD33 in human stem/progenitor cells enables immunotherapy against leukemia

When prey becomes predator

Scorpion venom used to fight S. aureus and M. tuberculosis

BeiGene updates on clinical results with zanubrutinib

Colorectal tumors that metastasize do it early

TNF and tinnitus

Acer Therapeutics receives complete response letter from FDA for use of Edsivo

Positive results presented from phase IIb trial of BPX-04 for papulopustular rosacea

Imbrium plans phase II study of IMB-115 for insomnia associated with alcohol cessation

FDA clears IND for the PROTAC protein degrader ARV-471

phiMR-003, a promising new therapeutic phage for MRSA infection

Positive topline phase I data support continued development of RDN-929

Statistical significance not achieved for the primary or secondary endpoints of the SOLACE study

EC grants marketing authorization for Doptelet for severe thrombocytopenia in adults with CLD

Researchers unveil LRP6 gene to be associated with familial hypercholesterolemia

Bionomics patents nicotinic alpha7 receptor negative allosteric modulators

Study gives insights into Parkinson's beyond dopamine

New lactam derivatives acting as H3 receptor ligands with potential for the treatment of pain

Researchers identify new compounds for respiratory diseases

Cadila Healthcare discloses IRAK-4 inhibitors

AstraZeneca synthesizes new RAS mutant inhibitors

Vivace Therapeutics presents YAP1/TEAD interaction inhibitors

FDA issues complete response letter for Ryaltris NDA

Phase IIb study of SPI-1005 in Meniere's disease meets endpoints

Promising first data for [212Pb]DOTAMTATE in patients with SSTR-positive neuroendocrine tumors

FDA allows Translate Bio to begin SAD phase I/II study of MRT-5201 for OTC deficiency

Faron reports interim data from phase II INFORAAA study of Traumakine

NantKwest cleared to begin first-in-human study with PD-L1 t-haNK cell therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...